3.
广泛期小细胞肺癌一线化疗OS和PFS的单因素分析
Univariate analysis of OS and PFS in extensive-stage SCLC patients who received first-line chemotherapy
| Factor | n | OS (95%CI) | χ2 | P | PFS (95%CI) | χ2 | P | ||
| EP: etoposide+cisplatin; CE: carboplatin+etoposide; PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response. | |||||||||
| Sex | 2.520 | 0.112 | 4.058 | 0.044 | |||||
| Male | 285 | 14.3 (12.66-15.94) | 7.2 (6.70-7.70) | ||||||
| Female | 84 | 17.0 (13.19-20.75) | 7.8 (5.27-10.33) | ||||||
| Age (yr) | 5.406 | 0.020 | 0.268 | 0.605 | |||||
| ≥60 | 213 | 13.4 (10.81-15.93) | 7.3 (6.78-7.82) | ||||||
| ＜60 | 156 | 15.6 (13.71-17.43) | 7.7 (7.08-8.38) | ||||||
| Smoking history | 3.736 | 0.053 | 7.335 | 0.007 | |||||
| Yes | 280 | 14.1 (12.08-16.13) | 7.2 (6.62-7.78) | ||||||
| No | 89 | 16.8 (14.36-19.24) | 8.4 (5.87-10.99) | ||||||
| ECOG PS | 7.664 | 0.006 | 2.112 | 0.146 | |||||
| 0-1 | 297 | 15.6 (14.05-17.10) | 7.6 (6.89-8.31) | ||||||
| 2-4 | 72 | 13.0 (9.01-16.99) | 7.2 (6.42-7.92) | ||||||
| Brain metastasis | 1.369 | 0.242 | 0.013 | 0.909 | |||||
| Yes | 67 | 11.8 (5.92-17.68) | 7.6 (6.92-8.22) | ||||||
| No | 302 | 15.4 (13.71-17.09) | 7.4 (6.89-7.80) | ||||||
| Liver metastasis | 22.794 | < 0.001 | 7.879 | 0.005 | |||||
| Yes | 71 | 9.4 (7.61-11.19) | 6.9 (5.10-8.64) | ||||||
| No | 298 | 16.5 (15.23-17.77) | 7.7 (7.14-8.32) | ||||||
| Bone metastasis | 23.212 | < 0.001 | 20.231 | < 0.001 | |||||
| Yes | 118 | 10.2 (8.33-12.01) | 5.4 (4.21-6.53) | ||||||
| No | 251 | 16.8 (15.03-18.57) | 8.1 (7.33-8.81) | ||||||
| Adrenal metastasis | 0.109 | 0.741 | 0.694 | 0.405 | |||||
| Yes | 61 | 14.9 (11.35-18.45) | 7.9 (6.96-8.90) | ||||||
| No | 308 | 15.4 (13.44-17.30) | 7.5 (6.98-7.96) | ||||||
| Malignant pleural fluid | 0.827 | 0.363 | 0.800 | 0.371 | |||||
| Yes | 95 | 15.6 (13.01-18.13) | 7.6 (6.81-8.39) | ||||||
| No | 274 | 14.8 (12.99-16.67) | 7.5 (6.93-8.01) | ||||||
| Chemotherapy regimen | 4.956 | 0.084 | 0.716 | 0.699 | |||||
| CE regimen | 230 | 14.9 (13.12-16.68) | 7.7 (6.95-8.45) | ||||||
| EP regimen | 75 | 17.4 (13.23-21.51) | 7.2 (6.14-8.26) | ||||||
| Other regimens | 64 | 11.5 (9.20-13.80) | 7.4 (6.40-8.34) | ||||||
| Curative effect | 62.003 | < 0.001 | 145.099 | < 0.001 | |||||
| PD | 28 | 5.9 (3.48-8.32) | 2.0 (1.39-2.61) | ||||||
| SD | 79 | 13.4 (9.82-16.92) | 5.9 (4.28-7.52) | ||||||
| PR/CR | 197 | 16.6 (15.21-17.93) | 8.2 (7.51-8.96) | ||||||
| Unknown | 65 | 10.0 (7.20-12.80) | 8.4 (5.23-11.63) | ||||||
| Cycle number | 67.903 | < 0.001 | 84.932 | < 0.001 | |||||
| 1-3 | 102 | 7.7 (5.62-9.78) | 3.2 (2.53-3.93) | ||||||
| 4-6 | 221 | 16.4 (14.93-17.87) | 7.6 (7.08-8.06) | ||||||
| ≥7 | 46 | 16.6 (14.50-18.64) | 10.6 (8.90-12.36) | ||||||
| Thoracic radiotherapy | 14.557 | < 0.001 | 10.744 | 0.001 | |||||
| Yes | 164 | 18.6 (14.51-22.75) | 8.9 (7.80-9.95) | ||||||
| No | 13.1 (10.94-15.20) | 6.9 (6.00-7.74) | |||||||
| Recurrence status | 37.415 | < 0.001 | 170.031 | < 0.001 | |||||
| Resistant | 158 | 11.6 (9.96-13.31) | 5.1 (4.71-5.54) | ||||||
| 3-6 months | 52 | 18.5 (14.38-22.68) | 12.8 (11.52-14.14) | ||||||
| ≥6 months | 31 | 24.9 (11.30-38.56) | 13.2 (8.96-17.51) | ||||||
| Unknown | 128 | 13.2 (8.96-17.51) | 8.4 (7.61-9.25) | ||||||